KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Leases (2019 - 2025)

BeOne Medicines (ONC) has disclosed Current Leases for 7 consecutive years, with $20.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 17.76% to $20.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.7 million, a 17.76% increase, with the full-year FY2025 number at $20.7 million, up 17.76% from a year prior.
  • Current Leases was $20.7 million for Q4 2025 at BeOne Medicines, up from $15.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $24.8 million in Q2 2022 to a low of $14.0 million in Q1 2021.
  • A 5-year average of $20.2 million and a median of $20.0 million in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 63.61% in 2022, then decreased 24.89% in 2024.
  • BeOne Medicines' Current Leases stood at $21.9 million in 2021, then rose by 9.65% to $24.0 million in 2022, then dropped by 8.7% to $22.0 million in 2023, then dropped by 19.93% to $17.6 million in 2024, then grew by 17.76% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Current Leases are $20.7 million (Q4 2025), $15.7 million (Q3 2025), and $17.2 million (Q2 2025).